Skip to main content
. 2012 Jul 17;206(10):1577–1588. doi: 10.1093/infdis/jis395

Figure 1.

Figure 1.

Experimental protocols used in studies of nanoformulated antiretroviral therapy (nanoART) efficacy and toxicology profiles. A, Treatment paradigm to determine pharmacokinetics and tissue distribution of nanoART (M2001 [atazanavir, ATV] + M3001 [ritonavir, RTV]; 80, 150, or 250 mg/kg each drug) by subcutaneous administration to NSG mice on days 0 and 7. B, Treatment paradigm to determine preinfection antiviral activity of nanoART (H2001 [ATV] + H3001 [RTV]; 250 mg/kg each drug) by subcutaneous administration on day 0 to human peripheral blood lymphocyte (huPBL)–reconstituted NSG mice 24 h prior to human immunodeficiency virus type 1 (HIV-1) infection. C, Treatment paradigm to determine antiviral activity of nanoART (H2001 + H3001, 250 mg/kg each drug or H2001 + H3001 + H4001 [efavirenz, EFV], 100 mg/kg each drug) by subcutaneous administration on days 0 and 7 to PBL-reconstituted, HIV-1–infected NSG mice.